Novo Nordisk A/S announced a share repurchase programme that will run for 12 months, beginning on February 4, 2026, and allowing the company to buy back up to DKK 15 billion of its B‑class shares. The initial tranche is capped at DKK 3.8 billion and will be executed between February 4 and May 4, 2026. As of March 20, 2026, the company had already repurchased DKK 2.09 billion of B shares at an average price of DKK 266.53 per share.
The programme is the largest share‑repurchase initiative announced by Novo in the current fiscal year and is intended to enhance shareholder value by reducing the number of outstanding shares. Management views the buy‑back as a sign of confidence in the company’s cash‑flow generation, which is underpinned by strong performance in its Diabetes and Obesity Care segment, where demand for GLP‑1 therapies such as Ozempic and Wegovy remains robust. At the same time, Novo faces pricing headwinds and increased competition in 2026, which could pressure sales and operating profit, prompting the company to balance shareholder returns with prudent capital allocation.
CEO Mike Doustdar has highlighted the company’s updated 2026 sales guidance, forecasting a decline of 5% to 13% at constant exchange rates due to pricing pressures and competition. He noted that “price reduction, in some ways, is our investment for the future and for capturing more patients,” underscoring the company’s strategy to maintain market share while returning capital to shareholders.
The share repurchase is supported by cash flow from the Diabetes and Obesity Care segment, which has experienced strong demand for its GLP‑1 products. The Rare Disease and other segments also contribute to the company’s overall liquidity, enabling Novo to fund the buy‑back without compromising its investment in research and development or other growth initiatives.
The programme could influence Novo’s debt‑to‑equity ratio and earnings per share in the coming quarters. By reducing equity, the buy‑back may increase the debt‑to‑equity ratio if debt levels remain unchanged, while the reduction in share count is expected to lift EPS. The capital allocation decision signals management’s confidence in the company’s long‑term financial health, even as it navigates pricing headwinds and competitive pressures.
The buy‑back is conducted under Article 5 of Regulation No 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (Safe Harbour Rules), ensuring compliance with European market‑authorisation requirements for share repurchases.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.